Acurx Pharmaceuticals (NASDAQ:ACXP) Earns “Buy” Rating from HC Wainwright

Acurx Pharmaceuticals (NASDAQ:ACXP)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a report issued on Tuesday,Benzinga reports. They presently have a $31.00 price objective on the stock.

Separately, Wall Street Zen raised Acurx Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, September 21st. One research analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $31.00.

Acurx Pharmaceuticals Stock Down 2.6%

Shares of NASDAQ ACXP traded down $0.11 during midday trading on Tuesday, hitting $4.17. The stock had a trading volume of 45,040 shares, compared to its average volume of 132,327. The company has a market capitalization of $6.59 million, a price-to-earnings ratio of -0.39 and a beta of -1.29. Acurx Pharmaceuticals has a 1-year low of $3.80 and a 1-year high of $44.00. The company has a fifty day moving average price of $5.11 and a 200 day moving average price of $7.21.

Acurx Pharmaceuticals (NASDAQ:ACXP) last released its quarterly earnings data on Monday, August 11th. The company reported ($1.89) earnings per share for the quarter, beating the consensus estimate of ($2.00) by $0.11. On average, research analysts forecast that Acurx Pharmaceuticals will post -0.89 EPS for the current year.

Institutional Investors Weigh In On Acurx Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. O Brien Greene & Co. Inc purchased a new stake in Acurx Pharmaceuticals during the 2nd quarter worth approximately $31,000. Vanguard Capital Wealth Advisors bought a new stake in shares of Acurx Pharmaceuticals in the 1st quarter valued at approximately $26,000. Prospect Financial Services LLC increased its holdings in shares of Acurx Pharmaceuticals by 11.4% in the 1st quarter. Prospect Financial Services LLC now owns 366,576 shares of the company’s stock valued at $143,000 after acquiring an additional 37,500 shares during the last quarter. Finally, Armistice Capital LLC bought a new stake in shares of Acurx Pharmaceuticals in the 2nd quarter valued at approximately $551,000. 11.53% of the stock is currently owned by hedge funds and other institutional investors.

Acurx Pharmaceuticals Company Profile

Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.